Pharming Group Nv ( (PHAR) ) has released its Q4 earnings. Here is a breakdown of the information Pharming Group Nv presented to its investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases, with a strong presence in the protein replacement and precision medicine sectors. In its latest earnings report, Pharming Group announced a 21% increase in total revenues for 2024, reaching $297.2 million, driven by record sales of RUCONEST® and substantial growth in Joenja® revenues. The company also reported a significant increase in fourth-quarter revenues and operating profit, highlighting its financial strength. Key financial metrics include a 9% rise in RUCONEST® revenues and a 147% increase in Joenja® revenues for the full year. Additionally, Pharming completed the acquisition of Abliva AB, enhancing its clinical pipeline with KL1333 for mitochondrial diseases. Looking ahead, Pharming aims to continue its growth trajectory by expanding its product offerings and advancing clinical trials, positioning itself for long-term value creation.